| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 01/24/2002 | WO2000073338A9 Compositions and methods for the therapy, diagnosis and monitoring of breast cancer |
| 01/24/2002 | WO2000059492A3 Anti-tumor activity of vitamin e, cholesterol, taxol and betulinic acid derivatives |
| 01/24/2002 | WO2000056303A3 Treatment of immune diseases |
| 01/24/2002 | US20020010949 Cloning using donor nuclei from differentiated fetal and adult cells |
| 01/24/2002 | US20020010357 Heat resistance dosage forms |
| 01/24/2002 | US20020010351 Anticancer agents |
| 01/24/2002 | US20020010344 Polycyclic aryl and heteroaryl substituted 1,4-quinones useful for selective inhibition of the coagulation cascade |
| 01/24/2002 | US20020010325 Complexing; purified polypeptide |
| 01/24/2002 | US20020010316 Thiazole derivatives |
| 01/24/2002 | US20020010315 Treatment or amelioration of symptoms of adult respiratory distress syndrome, septic shock, and multiple organ failure. |
| 01/24/2002 | US20020010211 Use of alpha-linolenic acid metabolites for treatment or prevention of cancer |
| 01/24/2002 | US20020010208 Dha-pharmaceutical agent conjugates of taxanes |
| 01/24/2002 | US20020010206 Treating cyclooxygenase-2 mediated disorders. |
| 01/24/2002 | US20020010203 Methods of modulating c-kit tyrosine protein kinase function with indolinone compounds |
| 01/24/2002 | US20020010190 N-heterocyclic derivatives as NOS inhibitors |
| 01/24/2002 | US20020010185 Anticarcinogenic agents |
| 01/24/2002 | US20020010181 Angiogenesis inhibitors as antitumor agents |
| 01/24/2002 | US20020010170 Pyrimido(1,6-b)pyridazine derivatives used as p38 inhibitors a mammalian protein kinase is involved in cell proliferation, cell death and response to extracellular stimuli |
| 01/24/2002 | US20020010169 Substituted 1, 4-thiazepine and analogs as activators of caspases and inducers of apoptosis and the use thereof |
| 01/24/2002 | US20020010168 Boswellic acid, salt or derivatives for preventing and/or combatting diseases caused by increased leucocytic elastase or plasmin activity in human or veterinary medincine, usedfor pulmonary emphysema, acute respiratory distress etc. |
| 01/24/2002 | US20020010165 Treating the hypercalcemia associated with malignant or neoplastic cells with an effective amount of a hypocalcemic vitamin D compound having a hydrocarbon moiet at the 24 position |
| 01/24/2002 | US20020010163 Pregnacalciferol derivatives and corresponding 5,6-trans isomers exhibit anti-progesterone activity and may be useful as antineoplastic, antifertility, antiproliferative, immunosuppressive or antiinflammatory agents |
| 01/24/2002 | US20020010146 Nitrosated and nitrosylated taxanes, compositions and methods of use |
| 01/24/2002 | US20020010125 Chemokinesis interferes with immune and inflammatory responses by increasing cell movements and altering cell migration patterns; interfere with spread of malignant cells through the body, and reduce inflammatory responses |
| 01/24/2002 | US20020009773 Nucleotide sequences coding protein associated with apoptosis; for use in treatment of defects of apoptosis and inflammation |
| 01/24/2002 | US20020009758 Compositions and methods for the therapy and diagnosis of lung cancer |
| 01/24/2002 | US20020009740 Methods for drug discovery, disease treatment, and diagnosis using metabolomics |
| 01/24/2002 | US20020009510 Plant extracts for the treatment of increased bone resorption |
| 01/24/2002 | US20020009501 Preparation of cartilage extracts using organic solvents |
| 01/24/2002 | US20020009491 Compositions and methods for enhancing drug delivery across biological membranes and tissues |
| 01/24/2002 | US20020009469 Low dose haptenized tumor cell and tumor cell extract immunotherapy |
| 01/24/2002 | US20020009455 Prostate glands; diagnosis, therapy |
| 01/24/2002 | US20020009446 Method of modulating memory effector T-cells and compositions |
| 01/24/2002 | US20020009444 Brain disorders using monoclonal antibodies |
| 01/24/2002 | US20020009430 Isolation of tumor cells; incubation |
| 01/24/2002 | US20020009428 Combination therapy for cancer |
| 01/24/2002 | US20020009427 Methods of therapy for non-hodgkin's lymphoma |
| 01/24/2002 | US20020009417 Nucleosome-based anti-tumor compositions |
| 01/24/2002 | DE10033283A1 Verwendung eines flüssigen Medikamentes zur Behandlung von Dissektionsebenen Resektionsflächen an einer biologischen Struktur und zur gleichzeitigen Trennung der biologischen Struktur und Hochdruckflüssigkeitsstrahleinrichtung zur Durchführung des Verfahrens Use of a liquid medicament for the treatment of Dissektionsebenen resection surfaces on a biological structure, and for the simultaneous separation of the biological structure and high pressure liquid jet means for performing the method |
| 01/24/2002 | DE10033245A1 Verwendungen des Hitzeschockproteins gp96 Uses of the heat shock protein gp96 |
| 01/24/2002 | DE10032608A1 Für mikrosatelliteninstabile (MSI+)-Tumore relevante Gene und ihre Genprodukte For microsatellite instability (MSI +) - related tumors genes and their gene |
| 01/24/2002 | DE10030466A1 Nukleotid- und Aminosäurensequenzen eines zellulären Repressors der DNA Replikation des Herpesvirus Epstein-Barr Nucleotide and amino acid sequences of a cellular repressor of DNA replication of the herpes virus Epstein-Barr |
| 01/24/2002 | CA2418391A1 Compositions and methods for the therapy and diagnosis of ovarian cancer |
| 01/24/2002 | CA2418146A1 Use of matrix metalloprotease inhibitors for the treatment of cancer |
| 01/24/2002 | CA2416813A1 Mutated pf-4, its fragments and mutated fusion peptides, their analogues, corresponding dna, cdna and mrna sequences and their use for inhibiting angiogenesis |
| 01/24/2002 | CA2416693A1 Phosphatonin-related gene and methods of use thereof |
| 01/24/2002 | CA2416452A1 Novel proteins and nucleic acids encoding same |
| 01/24/2002 | CA2416445A1 Human rrp sequences and methods of use |
| 01/24/2002 | CA2416285A1 Method of diagnosing, monitoring, staging, imaging and treating colon cancer |
| 01/24/2002 | CA2416187A1 Use of 2.alpha.-methyl-19-nor-20(s)-1.alpha.,25-dihydroxyvitamin d3 to increase bone strength |
| 01/24/2002 | CA2416153A1 Mutant rad51 paralog genes and use thereof in anticancer therapy |
| 01/24/2002 | CA2416015A1 Matrix metalloproteinase inhibitors |
| 01/24/2002 | CA2415961A1 Production method of 1-substituted-1,2,3-triazole derivatives |
| 01/24/2002 | CA2415896A1 Use of fluorescein derivatives for the treatment of diseases responsive to the activation of the cystic fibrosis transmembrane conductance regulator chloride channel |
| 01/24/2002 | CA2415701A1 Compositions and methods for the treatment of skin damage |
| 01/24/2002 | CA2415690A1 Tetraspan protein and uses thereof |
| 01/24/2002 | CA2415665A1 Pyrrolidine-2-carboxylic acid hydrazide derivatives for use as metalloprotease inhibitors |
| 01/24/2002 | CA2415557A1 Compounds for the treatment of sexual dysfunction |
| 01/24/2002 | CA2414780A1 Ophthalmic formulation of a selective cyclooxygenase-2 inhibitory drug |
| 01/23/2002 | EP1174440A1 A selectively-expressed epitope on the human CD38 molecule detected by a phage display library-derived human scFv antibody fragment |
| 01/23/2002 | EP1174438A1 Novel cyclic tetrapeptide derivatives and use thereof as drugs |
| 01/23/2002 | EP1174427A1 Method for pulvirizing to fine powder |
| 01/23/2002 | EP1174424A1 3-methylated vitamin d derivatives |
| 01/23/2002 | EP1174149A1 Proliferation inhibitor for androgen-independent tumor |
| 01/23/2002 | EP1174142A2 Immunopotentiator comprising peptide and hyaluronic acid |
| 01/23/2002 | EP1174129A1 Use of a matrix-metalloprotease inhibitor for the treatment of cancer |
| 01/23/2002 | EP1174126A1 Antibody and polyalkylene glycol-bonded liposome |
| 01/23/2002 | EP1173767A1 Peptide epitopes recognized by disease promoting cd4+ t lymphocytes |
| 01/23/2002 | EP1173765A1 Diagnostic and therapeutic use of antibodies against the urokinase receptor |
| 01/23/2002 | EP1173600A2 Cationic peg-lipids and methods of use |
| 01/23/2002 | EP1173598A1 A herpes simplex virus type 1 (hsv-1)-derived vector for selectively inhibiting malignant cells and methods for its use to treat cancers and to express desired traits in malignant and non-malignant mammalian cells |
| 01/23/2002 | EP1173587A1 Dsp-10 dual-specificity map kinase phosphatase |
| 01/23/2002 | EP1173586A1 Dsp-8 dual-specificity map kinase phosphatase |
| 01/23/2002 | EP1173569A1 Synthetic signalling molecules |
| 01/23/2002 | EP1173566A2 Human membrane-associated proteins |
| 01/23/2002 | EP1173563A1 Compositions and methods for the treatment of tumour |
| 01/23/2002 | EP1173562A2 Inhibition of histone deacetylase |
| 01/23/2002 | EP1173561A2 Non-invasive method for detecting target rna |
| 01/23/2002 | EP1173552A2 Carbohydrate-modifying enzymes |
| 01/23/2002 | EP1173480A2 Stereoselective antifibrillogenic peptides and peptidomimetics thereof |
| 01/23/2002 | EP1173479A1 49 human secreted proteins |
| 01/23/2002 | EP1173478A1 49 human secreted proteins |
| 01/23/2002 | EP1173477A1 49 human secreted proteins |
| 01/23/2002 | EP1173476A1 Soybean protein nutraceuticals |
| 01/23/2002 | EP1173469A2 Adhesion modulatory peptides and methods for use |
| 01/23/2002 | EP1173468A1 Integrin receptor antagonists |
| 01/23/2002 | EP1173462A1 50 human secreted proteins |
| 01/23/2002 | EP1173443A1 Cyclic urea and cyclic amide derivatives |
| 01/23/2002 | EP1173441A1 6-alkenyl-, 6-alkinyl- and 6-epoxy-epothilone derivatives, process for their production, and their use in pharmaceutical preparations |
| 01/23/2002 | EP1173433A1 Cyanopyrroles as progesterone receptor agonists |
| 01/23/2002 | EP1173427A1 Hydroxamic acid derivative |
| 01/23/2002 | EP1173426A1 Cyclocarbamate derivatives as progesterone receptor modulators |
| 01/23/2002 | EP1173423A1 Benzimidazolones and analogues and their use as progesterone receptor ligands |
| 01/23/2002 | EP1173422A1 Bis-benzazoles and their use as antineoplastic agents |
| 01/23/2002 | EP1173420A2 Heterocyclic compounds having antitumor activity |
| 01/23/2002 | EP1173414A1 N-protected amines and their use as prodrugs |
| 01/23/2002 | EP1173413A1 Use of 2,4-diamino-3-hydroxycarboxylic acid derivatives as proteasome inhibitors |
| 01/23/2002 | EP1173252A1 Products and methods for brachytherapy |
| 01/23/2002 | EP1173225A2 Agent for gene therapy and for the prevention of metastases, as well as for the gene therapy of tumors |
| 01/23/2002 | EP1173224A1 Polyethyleneimine:dna formulations for aerosol delivery |